Comparing the current results to its competitors, Stevanato Group S P A reported Revenue increase in the 4 quarter 2025 by 7.45 % year on year. The revenue growth was below Stevanato Group S P A 's competitors' average revenue growth of 9.42 %, achieved in the same quarter.
Stevanato Group S p a Net Income in the 4 quarter 2025 grew year on year by 18.74%, while most of its competitors have experienced a contraction in net income by -24.44 %.
October 1, 2024
In a bold move poised to reshape the landscape of injectable therapies, Stevanato Group S.p.A. (NYSE: STVN), a distinguished leader in the realms of drug containment and delivery solutions, has announced the expansion of its innovative Vertiva platform with the introduction of a robust 10mL On-Body Delivery System. This significant development will be showcased at the upcoming CPHI Milan in October, marking a pivotal moment for the company and the industry at large.The Vertiva platform, lauded for its user-centric design and versatility, is engineered to accommodate a myriad of dosing profiles. With preset functionalities that allow for everything from micro-precision basal delivery to full-capacity administ...
May 30, 2024
Stevanato Group Expands Operations with New State-of-the-Art Plant in Cisterna di LatinaPIOMBINO DESE, Italy - Stevanato Group S.p.A. (NYSE: STVN), a renowned global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, has announced the opening of its cutting-edge plant in Cisterna di Latina. This new facility, spanning an impressive 65,000 square meters and employing about 200 skilled workers, is located just a few kilometers away from the Group s first historic plant in Latina.The Cisterna di Latina plant marks a significant milestone in Stevanato Group s commitment to innovation and excellence in the field of drug containm...
May 24, 2024
Stevanato Group, a prominent global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, declared the positive outcome of its Annual General Meeting of Shareholders (AGM) held virtually on May 22, 2024. The company proudly revealed that all proposed resolutions were approved by the shareholders, further demonstrating their trust and confidence in the company s vision and strategic initiatives.During the AGM, the resolutions presented to the shareholders were thoroughly discussed and analyzed, reflecting Stevanato Group s commitment to transparency and accountability. The informative report provided detailed insights into the...
January 24, 2024
With the goal of optimizing pharmaceutical procedures and streamlining production, Italy s Stevanato Group S.p.A (NYSE: STVN), a leading global provider of drug containment and delivery solutions, has engaged in the unveiling of two admirable and promising inventions. Positioned to redefine efficiency in small-batch pharmaceutical manufacturing, the company’s latest release includes the EZ-fill Kit and a non-GMP laboratory fill and finish service at their Technology Excellence Centers (TEC).The innovative solutions arriving from the Stevanato Group confirm not only the company s technological excellence but also its constant investing into the world of biotechnology and pharmaceuticals. The simultaneous re...
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
The Cooper Companies Inc is a global medical device firm focused on manufacturing and distributing contact lenses and womens healthcare products. Its business model emphasizes innovation, strong distribution, strategic acquisitions, and partnerships to enhance market presence, targeting the specific needs of customers in eye care and womens health. Through research and development, they aim to improve customer lives while maximizing shareholder value.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Stryker Corps business model focuses on innovation in medical technologies and devices, specializing in areas such as orthopedics, surgical equipment, and neurotechnology, to enhance patient care and improve outcomes in the healthcare industry.
AptarGroup Inc is a global provider of packaging solutions, specializing in dispensing systems and closures for a wide range of industries. Their business model revolves around designing and manufacturing innovative packaging solutions that enhance product functionality and consumer experience, catering to the needs of various market sectors.
Sources:
Stevanato Group S p a’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Stevanato Group S p a versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
